Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), announces a definitive agreement (the “Garda Agreement”) to be acquired by Garda Therapeutics (“Garda” or the “Buyer”) for $18 per share in cash, or a total cash consideration of $125.1 million, (the “Garda Transaction”), plus a contingent value right (the “CVR”). In connection with the Garda Transaction, the Company today also announced that it has signed and closed an agreement (“Cosette Agreement”) to sell all non-Rolvedon assets to Cosette Pharmaceuticals (“Cosette”).
Read the full article: Assertio Announces Agreement to Be Acquired by Garda Therapeutics //
Source: https://www.businesswire.com/news/home/20260408108552/en/Assertio-Announces-Agreement-to-be-Acquired-by-Garda-Therapeutics